Matthew C Kapusta
CIK 1536290 · CEO, Managing Director · last filed 2026-07-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
QURE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
GERMANTOWN, TN 38138
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QURE | CEO, Managing Director | 519,227 | $24.83 | $12.89M | -$50.18M | 69 | 2026-07-07 |
| Decibel Therapeutics, Inc. (DBTX) Delisted | Director | 0 | $4.91 | $0 | $0 | 2 | 2023-09-25 |
| ANGIODYNAMICS INC (ANGO.V) Delisted | SVP, Business Development | 30,062 | — | — | $11.4K | 11 | 2014-11-19 |
Recent Filings · Page 3 of 10
92 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-05 | QURE | Grant (A) | +150,000 | $0 | EDGAR |
| 2024-02-28 | QURE | Sell (S) | −27,904 | -$177.2K | EDGAR |
| 2024-02-26 | QURE | Notice (144) | −27,904 | -$180.5K | EDGAR |
| 2023-09-25 | Decibel Therapeutics, Inc. (DBTX) Delisted | Disp (D) | −10,000 | $0 | EDGAR |
| 2023-03-21 | Decibel Therapeutics, Inc. (DBTX) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
| 2023-03-09 | QURE | Sell (S) | −2,521 | -$53.9K | EDGAR |
| 2023-03-01 | QURE | Sell (S) | −24,547 | -$493.3K | EDGAR |
| 2023-02-27 | QURE | Grant (A) | +121,500 | $0 | EDGAR |
| 2023-02-22 | QURE | Grant (A) | +5,830 | $0 | EDGAR |
| 2022-12-13 | QURE | Sell (S) | −6,648 | -$149.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.